Date: Thu, 3 Oct 1996 11:48:39 -0400 From: "Flynn Mclean" Subject: New Educational Materials 10/04/96 CDC National AIDS Clearinghouse Educational Materials Database NEW MATERIALS October 4, 1996 The Clearinghouse's Educational Materials Databases contain bibliographic information about more than 14,000 brochures, videos, booklets, and other materials with education/prevention messages. NAC ONLINE users can search these databases by selecting "Clearinghouse Databases" from the NAC ONLINE main menu. When asked to enter a database name, specify "UNPB" (which stands for unpublished materials) to search all materials, regardless of availability; "CNPB" (which stands for current materials) to search only materials currently available from the distributor; or "ANPB" (which stands for archival materials) to search only materials which are no longer available. To access the NAC ONLINE BBS, set your communications software to dial (800) 851-7245, and set the options for 8 data bits, N parity, 1 stopbit, full duplex, and complete a new user questionnaire. Only non-profit organizations, government agencies, educational institutions, and health departments are given full access to NAC ONLINE and the NAC databases. Over the weekend, 13 newly catalogued materials were loaded to the UNPB Educational Materials Database. This brings the total number of materials on the Database to 17,641. Document 1 AN AD0020181. TI Time to Hit HIV, Early and Hard. FM 24 - Journal Article. Print Material. 44 - Reprint. Print Material. AC 117 - Researchers. 170 - Physicians. AV Massachusetts Medical Society Medical Publishing Group New England Journal of Medicine 1440 Main St. Waltham, MA 02154-1649. (617) 893-3800. Attn: Bulk Reprint Department. AB This editorial advocates the early treatment of asymptomatic HIV type 1 (HIV-1). The author discusses the results of the AIDS Clinical Trials Group study showing that immediate zidovudine therapy, as compared with deferred treatment, in asymptomatic persons with CD4 lymphocyte counts of 500 or more does not prolong the disease-free period or confer a survival benefit. However, findings from Kinloch-de Loes, et al shows that the use of zidovudine early, during primary HIV-1 infection and 6 months thereafter, results in a detectible improvement in the clinical course of the disease as well as an increase in the CD4 cell count. The contradictory nature of these findings is explained in light of recent observations on the pathogenesis of HIV-1. The author favors aggressive combination therapy at the outset of disease when the virus' DNA is most homogeneous. Studies have shown that after a few years of infection, every viable mutation at every position in the HIV genome will occur. This, the author says, means monotherapy as we know it is doomed to fail. In the long run, effective treatment must instead force the virus to mutate simultaneously at multiple positions. This is best achieved by using a combination of several powerful antiretroviral agents. MJ Pharmaceutical research . Clinical trials . Etiology . Experimental treatment . Therapeutic drugs . Symptoms . Asymptomatic infection . Document 2 AN AD0020183. TI Protease Inhibitors: Choices and Analysis. FM 39 - Paper. Print Material. AC 117 - Researchers. 170 - Physicians. 400 - Persons With AIDS. 445 - HIV Positive Persons. AV Project Inform HIV Treatment Hotline 1965 Market St., Ste. 220 San Francisco, CA 94103. (800) 822-7422. A photocopy of this material is available from the CDC National AIDS Clearinghouse Document Delivery Service P.O. Box 6003 Rockville, MD 20849-6003. (800) 458-5231. Price: $5.20. AB This discussion paper analyzes the key differences among three protease inhibitor drugs and clarifies emerging data and information on these therapies. Indinavir (Crixivan) ranks among the most potent anti-HIV therapies, consistently reducing viral load in both combination and monotherapy studies. Ritonavir used alone or in combination has shown the ability to suppress virus by at least 100-fold, and has exceeded that level when used in a three-drug combination. Saquinavir, the first protease inhibitor to be approved, has become a source of confusion because in its present form very little of it is sustained in the blood. Information about side effects, drug interactions, costs, and dosing is provided for each of these protease inhibitors. MJ Virology . Therapeutic drugs . Therapies . Treatment . Pharmacology . Document 3 AN AD0020184. TI The New Era in AIDS Treatment... One Chance to Use It Right or Lose It. FM 35 - NEWSLETTER ARTICLE. Print Material. 44 - Reprint. Print Material. AC 117 - Researchers. 170 - Physicians. 400 - Persons With AIDS. 445 - HIV Positive Persons. AV Project Inform HIV Treatment Hotline 1965 Market St., Ste. 220 San Francisco, CA 94103. (800) 822-7422. A photocopy of this material is available from the CDC National AIDS Clearinghouse Document Delivery Service P.O. Box 6003 Rockville, MD 20849-6003. (800) 458-5231. Price: $5.10. AB This newsletter article considers the use of the new protease inhibitors, ritonavir and indinavir. These drugs have proven to be potent, but they must be used with great care and deliberation. Without carefully chosen strategies, their benefits will be short lived and quickly followed by the development of multi-drug cross-resistance to most of the field of protease inhibitors. Results of clinical trials indicate that how these drugs are used impacts significantly how well and how long they work. Unless physicians and patients learn to use these drugs correctly, they will be rendered useless. The authors compare this with the treatment of tuberculosis. "Worst case", "sub-optimum case", and "best case" scenarios for the protease inhibitors are presented. MJ Virology . Therapeutic drugs . Therapies . Treatment . Pharmacology . Document 4 AN AD0020185. TI Antivirals A to Z. FM 22 - Fact Sheet. Print Material. AC 117 - Researchers. 170 - Physicians. 400 - Persons With AIDS. 445 - HIV Positive Persons. AV Project Inform HIV Treatment Hotline 1965 Market St., Ste. 220 San Francisco, CA 94103. (800) 822-7422. A photocopy of this material is available from the CDC National AIDS Clearinghouse Document Delivery Service P.O. Box 6003 Rockville, MD 20849-6003. (800) 458-5231. Price: $5.70. AB This fact sheet provides information about combination antiretroviral therapies. The rationale for antiviral therapy remains strong despite the inability of early drugs to produce long-term benefits when used alone. The fact sheet defines reverse-transcriptase inhibitors and antisense drugs and presents the Federal recommendations for antiviral therapies. Information about initiating treatment, determining whether or not treatment has been effective, and alternating treatments is also provided. The fact sheet evaluates specific reverse-transcriptase inhibitors (i.e., AZT, ddC, 3TC) and protease inhibitors (i.e. indinavir, saquinavir, ritonavir). MJ Treatment . Therapeutic drugs . Therapies . Pharmaceutical research . Pharmacology . Clinical trials . Document 5 AN AD0020186. TI Update on Protease Inhibitors. FM 22 - Fact Sheet. Print Material. AC 117 - Researchers. 170 - Physicians. 400 - Persons With AIDS. 445 - HIV Positive Persons. AV Project Inform HIV Treatment Hotline 1965 Market St., Ste. 220 San Francisco, CA 94103. (800) 822-7422. A photocopy of this material is available from the CDC National AIDS Clearinghouse Document Delivery Service P.O. Box 6003 Rockville, MD 20849-6003. (800) 458-5231. Price: $5.10. AB This fact sheet (draft and update) summarizes data from clinical trials of protease inhibitors. In general, protease inhibitors show very powerful anti-HIV activity in laboratory studies but have proven very difficult to manufacture. Results from new studies of indinavir show that it combines potent antiviral activity with modest side effects. Saquinavir has been tested as a monotherapy and in a variety of two- and three-drug combinations. Saquinavir appears to be far less active than the other approved protease inhibitors. A study of ritonavir shows that people with advance-stage HIV disease using the drug in addition to their standard therapies were significantly less likely to progress in disease or die compared to those receiving a placebo. Two small studies of nelfinavir are also noted. MJ Pharmaceutical research . Treatment . Therapeutic drugs . Medical treatment. Virology . Therapies . Pharmacology . Document 7 AN AD0020188. TI Sharing Success: A Replication Guide for Hispanic - Focused Model HIV / AIDS Education and Prevention Programs. FM 42 - Report. Print Material. AC 210 - Advocates. 230 - Educators. 673 - Community Organizations. 116 - Planners. AV National Council of La Raza 1111 19th St., NW., Ste. 1000 Washington, DC 20036. (202) 785-1670. AB This guide presents strategies that organizations can use to develop and prepare materials that will enable other organizations to replicate a model project. The first section outlines the components of a replication package, followed by a detailed sample format. The suggested format includes: an overview of the model; a description of the target group or entities; a listing of the specific, measurable objectives of the project and a description of essential and optional components; a project organization and flow paradigm; and an implementation plan that includes major tasks and specific subtasks and activities. Instructions for documentation and evaluation, presentation of evaluation results, and a list of project-related materials are also included. MJ Program development . Program evaluation . Community health planning . Evaluation methods . Models . Hispanics . Intervention strategies . Document 8 AN AD0020189. TI CDC Abstracts From the XIth International Conference on AIDS; Vancouver, BC, Canada, July 7-12, 1996. FM 02 - Abstract. Print Material. 40 - Proceedings. Print Material. AC 100 - Health Professionals. 116 - Planners. 117 - Researchers. 200 - Community Service Professionals. 632 - Federal Agencies. 400 - Persons With AIDS. 445 - HIV Positive Persons. AV CDC National AIDS Clearinghouse P.O. Box 6003 Rockville, MD 20849-6003. (800) 458-5231. CDC NAC Inventory no. D995; Single copies free of charge. AB This report contains the abstracts of posters, oral presentations, and other papers presented at an international AIDS conference. The presentations address a broad range of issues including but not limited to clinical trials, epidemiology, HIV prevention, infants, risk behaviors, women, youth, trends, surveillance, perinatal HIV, pregnancy, schools, seroprevalence, and injection drug use. The report contains a subject index and presenter index. MJ Information dissemination . International cooperation . Research programs . Clinical trials . HIV prevention . Professional education . Document 9 AN AD0020192. TI TB & Prisons: The Facts for Inmates and Officers. FM 08 - Brochure. Print Material. AC 295 - Law Enforcement and Correctional Personnel. 368 - Incarcerated Persons. 650 - Law Enforcement and Correctional Agencies. AV American Civil Liberties Union National Prison Project 1875 Connecticut Ave. NW., Ste. 410 Washington, DC 20009. (202) 234-4830. AB This pamphlet considers the incidence and prevalence of tuberculosis (TB) infection and disease in correctional institutions and describes the symptoms, diagnosis, treatment, and transmission of TB. Strategies for avoiding infection in the prison setting are outlined and include eliminating overcrowding and improving ventilation to reduce the risk of spreading TB. The link between HIV and TB is explained, and those who have HIV infection are instructed to get tested for TB infection at least twice per year. MJ Tuberculosis (TB) . Tuberculosis prevention . Incarcerated persons . Correctional facilities . Document 10 AN AD0020193. TI School - Based HIV - Prevention Education - United States, 1994. FM 42 - Report. Print Material. AC 230 - Educators. 304 - Administrators. 680 - Schools. AV CDC National AIDS Clearinghouse P.O. Box 6003 Rockville, MD 20849-6003. (800) 458-5231. CDC NAC Inventory no. D383; Single copies free of charge; $0.10 for each additional copies. AB The Centers for Disease Control and Prevention (CDC) conducted the School Health Policies and Programs Study (SHPPS) to assess five components of the school health program: health education, physical education, health services, food service, and health policies. This report summarizes findings from the health education component of the study. The findings indicate that although HIV-prevention education has been widely implemented in U.S. schools, improvement in these programs is needed. In particular, efforts are needed to increase the percentage of teachers who teach HIV prevention in a health education setting and who receive in-service training on HIV prevention. Current in-service training is vital for HIV education because new methods are being identified to assist youth in developing the skills needed to avoid HIV infection. MJ School policies . School health education . HIV/AIDS education needs. Teacher roles . Professional education . Studies . Health education needs .